share_log

港股异动 | 科伦博泰生物-B(06990)涨近4% ASCO发布数据进一步证实SKB264潜力

HKEX Changes | Kelunbotai Biopharmaceutical-B (06990) up nearly 4%, further confirming the potential of SKB264 with ASCO data release.

Zhitong Finance ·  Jun 17 09:44

Zhixing Finance APP learned that Kelunbotai Bio-B (06990) rose nearly 4%, as of the press release, up 3.98% to HKD 169.70, with a turnover of HKD 8.0459 million.

CMB International released a research report stating that at the American Society of Clinical Oncology (ASCO) annual meeting, Kelunbotai Bio-B's core product SKB264 is expected to achieve good efficiency in its opinion, and the product is expected to be widely used in non-small cell lung cancer (NSCLC), and the strong results of SKB264's Phase III clinical trial for triple-negative breast cancer will help it obtain approval in the mainland.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment